DZ Bank’s 10x Genomics TXG Stock Holding History

DZ Bank’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-88,900	Closed	-$17.5M	–	1005
2021 Q2	$17.5M	Buy	+88,900	New	+$16.1M	0.03%	296

Other funds holding TXG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

SIM

SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

DZ Bank's TXG Position: Q2 2022 in Review

DZ Bank sold out of 10x Genomics (TXG) in Q2 2022, closing a stake of 43,845 shares — an estimated $3.34M sold.

DZ Bank first reported a position in TXG in Q1 2021 and held it in 5 quarters. The position peaked at $18.5M in Q4 2021. 254 funds tracked by Wall St. Rank hold TXG as of Q2 2022.

DZ Bank reported no remaining 10x Genomics position as of Q2 2022 after selling out during the quarter.
DZ Bank sold 43,845 10x Genomics shares in Q2 2022, an estimated $3.34M.
DZ Bank first reported a position in 10x Genomics in Q1 2021 and held it in 5 quarters.
DZ Bank's 10x Genomics position peaked at $18.5M in Q4 2021.
254 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2022.

Based on DZ Bank's 13F filing for Q2 2022, filed 15 Aug 2022.